Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine plus erlotinib in advanced non-small cell lung cancer
NL-OMON21406Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydroxychloroquine and erlotinib in non-small cell lung cancer (NSCLC), sponsored by Vrije University Medical Center. Started Jul 2012; status: active, not recruiting.
02
Drugs
hydroxychloroquineerlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON21406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21406.